<DOC>
	<DOCNO>NCT00210951</DOCNO>
	<brief_summary>The purpose study assess incidence pure red cell aplasia ( PRCA [ suppression erythropoiesis little abnormality leukocyte platelet production ] ) among participant chronic renal failure ( CRF ) , receive treatment epoetin alfa exogenous recombinant erythropoietin therapy .</brief_summary>
	<brief_title>Study Monitor Incidence Pure Red Cell Aplasia ( PRCA ) and/or Antibodies Erythropoietin Among Participants Receiving Epoetin Alfa Another Erythropoietin</brief_title>
	<detailed_description>This prospective ( observation population sufficient number person sufficient number year generate incidence mortality rate subsequent selection study group ) , observational ( clinical study participant may receive diagnostic , therapeutic , types intervention , investigator assign participant specific intervention ) cohort study . Study specific information collect participant chronic renal disease receive recombinant erythropoietin treatment course follow 2 year participant receive intervention study . Upon enter study , information collect regard disease history recombinant erythropoietin treatment . Every 3 month thereafter , progress information collect , include recombinant erythropoietin treatment , number red blood cell presence sign pure red cell aplasia ( PRCA ) development . Blood sample collect study entry every 3 month . Participants discontinue erythropoietin follow additional 12 month time erythropoietin discontinue . Participants receive standard-of-care treatment chronic renal disease individual Investigators . Participants primarily observe prospectively PRCA .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Red-Cell Aplasia , Pure</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Male female participant legal age give consent accord local standard Participants must receive receive treatment erythropoietin part preexist treatment plan chronic renal ( ) disease Physicians treat participant must agree advance document appearance pure red cell aplasia ( PRCA ) information detail case may report regulatory agency ( patient identification protect ) If require local ethic committee , participant must give consent permit collection deidentified personal data specific purpose study collect blood sample test antibody erythropoietin Participants unable complete future followup visit Participants enter study follow symptom pure red cell aplasia ( PRCA ) : Loss effectiveness erythropoietin low number immature red blood cell erythropoietin show blood test bone marrow examination Participants history PRCA loss effectiveness erythropoietin time enrollment study Participants whose anemia respond previous treatment erythropoietin Participants history antibody erythropoietin prior entering study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Epoetin alfa</keyword>
	<keyword>Erythropoietin</keyword>
	<keyword>Red Cell Aplasia , Pure</keyword>
	<keyword>Chronic Renal Failure</keyword>
</DOC>